Story
Longeveron Shares Halve After Heart Drug Fails Key Clinical Trial
Summary
Longeveron Inc. (NASDAQ:LGVN) stock plummeted after its investigational stem cell therapy, laromestrocel, failed to meet the primary endpoint in a Phase 2b trial for a rare infant heart defect. The company has initiated a review of strategic options to maximize shareholder value.
Shares of Longeveron Inc. (NASDAQ:LGVN) plunged by 50% in premarket trading on Thursday after the biotechnology company announced its ELPIS II Phase 2b clinical trial did not meet its primary goal. The trial was evaluating the company's investigational stem cell therapy, laromestrocel, for a rare and complex congenital heart defect in infants.
Trial Fails to Meet Primary Endpoint
The ELPIS II study assessed the efficacy of laromestrocel in 40 infants with hypoplastic left heart syndrome (HLHS). The trial's primary efficacy endpoint was the change from baseline in right ventricular ejection fraction at the 12-month mark, a key measure of heart function.
Longeveron reported that the trial failed to show a statistically significant improvement in the treatment group compared to the control group. The key results included:
- The least-squares mean difference between the groups was -0.7 percentage points.
- The result was not statistically significant, with a p-value of 0.8336.
Company Explores Strategic Options
AdIn response to the trial results, Longeveron's management has initiated a process to review all strategic options with the stated goal of maximizing shareholder value. The company announced it plans to engage an investment bank to serve as a strategic advisor.
Alongside the strategic review, Longeveron will implement cash conservation measures to control costs. The company stated it still intends to discuss the full results with the U.S. Food and Drug Administration (FDA) to determine potential next steps for the HLHS development program.
Secondary Data and Future Plans
While the primary endpoint was missed, Longeveron noted some exploratory clinical outcomes. There were no deaths in the laromestrocel-treated group over 12 months, compared to one death in the control group. Major adverse cardiovascular events were approximately 31% fewer in the laromestrocel arm, though this analysis was also not statistically significant.
The company confirmed that laromestrocel's safety profile was consistent with prior trials and no new safety signals were identified. Longeveron said it plans to pursue funding to continue developing laromestrocel for other indications, including longevity and aging-related frailty, noting its recent selection as a finalist in the XPRIZE Healthspan competition.
Read next
More on Stocks
Record Diesel Prices Squeeze US Farmers, Threaten Higher Food Inflation
US farmers are facing record-high diesel costs during the crucial harvest season, a development that is squeezing profit margins and expected to push consumer food prices higher across the supply chain.
US Draft Rules to Permit Most Pharma Licensing Deals with China, Sources Say
The U.S. Treasury Department is reportedly drafting rules that would allow American pharmaceutical companies to continue most licensing deals with Chinese firms, sources say, avoiding broad restrictions sought by some lawmakers over national security concerns.
Century Aluminum's $4B Oklahoma Smelter Project Stalled by Local Opposition
A proposed $4 billion aluminum smelter in Oklahoma, backed by Century Aluminum and Emirates Global Aluminium, faces a prolonged local moratorium and a public referendum, creating significant uncertainty despite a key political victory for its supporters.
BofA Upgrades Equinor to 'Buy' on Bullish European Gas Price Forecast
BofA Securities raised its rating on Equinor to "Buy" from "Neutral," citing an improved outlook for European gas prices that is expected to significantly boost the energy company's cash flow. The bank also increased its price target to 465 Norwegian kroner.